54 results
8-K
VERV
Verve Therapeutics Inc
2 Apr 24
Other Events
7:13am
of safety and tolerability as well as changes in blood PCSK9 protein and low-density lipoprotein cholesterol (“LDL-C”) levels in patients living … , in consultation with the study’s independent data and safety monitoring board, has decided to pause enrollment in the Heart-1 trial. Verve is conducting
8-K
EX-99.1
VERV
Verve Therapeutics Inc
27 Feb 24
Verve Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results
7:45am
-101 is being evaluated in the Heart-1 Phase 1b clinical trial with endpoints of safety and tolerability as well as changes in blood PCSK9 protein … in the highest dose cohort. A review of the safety data of VERVE-101 by an independent data and safety monitoring board
supported the continued
8-K
EX-1.1
fgs7w7z
29 Nov 23
Verve Therapeutics Announces Pricing of Public Offering of Common Stock and Concurrent Private Placement
4:54pm
424B5
mbl7watzhvdp2d29 mi
29 Nov 23
Prospectus supplement for primary offering
4:47pm
424B5
o1pf0a
28 Nov 23
Prospectus supplement for primary offering
4:25pm
8-K
42fsoc
13 Nov 23
Other Events
6:34am
8-K
EX-99.1
cqp036
7 Nov 23
Verve Therapeutics Highlights Recent Company Progress and Reports Third Quarter 2023 Financial Results
7:00am
8-K
gla9qmrm8kevj
23 Oct 23
Other Events
6:41am
8-K
EX-99.1
nyr eyf05t
10 Aug 23
Verve Therapeutics Highlights Recent Company Progress and Reports Second Quarter 2023 Financial Results
7:00am
8-K
EX-99.1
9hugf 3ql3bjvdyr
15 May 23
Verve Therapeutics Announces Pipeline Progress and Expansion and Reports First Quarter 2023 Financial Results
7:00am
8-K
q2ssm
5 Dec 22
Other Events
6:47am